Findings presented at the American Society for Microbiology's ASM Microbe conference show that the ultra-sensitive Clostridium difficile toxin A/B assay in development for use on the Sgx Clarity™ ...

Clostridium difficile, a bacterium known to cause symptoms from diarrhea to life-threatening colon damage, is part of a growing epidemic for the elderly and hospitalized patients. Biologists have now ...

Clostridium difficile can proliferate when the gut's normal microbiome is killed by antibiotics, leading to inflammation. New research shows how the microbes' poisonous proteins penetrate intestinal ...

- The vaccine candidate was highly immunogenic in elderly subjects and was able to induce similar immune responses to Clostridium difficile toxins A and B as the ones observed in adults in part Ia of ...

In a hamster model of Clostridium difficile, infection with C. difficile strains producing either toxin A or toxin B caused fulminant disease, according to a research team from the University of ...

The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium, ...

A new study, led by researchers from the University of California, Irvine (UCI), uncovers the long-sought-after, three-dimensional structure of a toxin primarily responsible for devastating ...

Clostridium difficile infection (CDI) is a common hospital-acquired infection that is associated with a high clinical and economic burden. Because of this management of CDI is quickly becoming a part ...

BOSTON (Sept. 5, 2007) — As if being admitted to the hospital weren’t bad enough, patients, once admitted, are at higher risk of becoming infected with a “superbug” bacterium, Clostridium difficile (C ...

Clostridium difficile is an unpleasant, sometimes severe, and potentially lethal infection. It is an enteric pathogen whose armory involves the production of a toxin leading to gut dysphoria and ...

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide SWIFTWATER, Pa., Aug. 5, 2013 /PRNewswire/ -- Sanofi Pasteur, the vaccines ...

Vaccine candidate was highly immunogenic in all age groups tested and induced strong immune responses to both Clostridium difficile Toxins A and B (primary endpoint met) Good safety and tolerability ...